From TMC114 to darunavir: Five years of data on efficacy

AIDS Reviews

Volumn 15, Issue 2, 2013, Pages 112-121

  Llibre, Josep M ^a,b   Imaz, Arkaitz ^c   Clotet, Bonaventura ^a,b,d  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d AIDS Research Institute irsiCaixa   (Spain)

Author keywords

Antiretroviral treatment; Darunavir; HIV 1 treatment experienced; Treatment naive; Virologic failure

Indexed keywords

DARUNAVIR; DARUNAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; SULFONAMIDE;

BINDING AFFINITY; DOSAGE SCHEDULE COMPARISON; DRUG BINDING; DRUG EFFICACY; DRUG POTENCY; DRUG TREATMENT FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONOTHERAPY; REVIEW; SALVAGE THERAPY; VIREMIA; VIRUS RESISTANCE; ANTIVIRAL RESISTANCE; DRUG EFFECT; TREATMENT OUTCOME;

DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84883195223     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Dierynck I, De W, Gustin E, et al. Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier. J Virol. 2007;81:13845-51.
2. Ghosh A, Kincaid J, Cho W, et al. Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-(hydroxyethylamino)sulfonamide isostere. Bioorg Med Chem Lett. 1998;8:687-90.
3. Surleraux D, Tahri A, Verschueren W, et al. Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor. J Med Chem. 2005;48:1813-22.
4. De M, Azijn H, Surleraux D, et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother. 2005;49:2314-21.
5. Lefebvre E, Schiffer C. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir. AIDS Rev. 2008;10:131-42.
6. Haubrich R, Berger D, Chiliade P, et al. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS. 2007;21: F11-18.
7. Katlama C, Esposito R, Gatell J, et al. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS. 2007;21:395-402.
8. De Meyer S, Vangeneugden T, van Baelen B, et al. Resistance profile of darunavir: combined 24-week results from the POWER trials. AIDS Res Hum Retroviruses. 2008;24:379-88.
9. Johnson V, Calvez V, Gunthard H, et al. 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med. 2011;19:156-164.
10. Llibre J. Do we need genotypic weighted resistance scores for antiretrovirals? The curious case of tipranavir. Antivir Ther. 2010;15:959-61.
11. Clotet B, Bellos N, Molina J, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet. 2007;369:1169-78.
12. Llibre J, Schapiro J, Clotet B. Clinical implications of genotypic resistance to the newer antiretroviral drugs in HIV-1-infected patients with virological failure. Clin Infect Dis. 2010;50:872-81.
13. Molina J, Cohen C, Katlama C, et al. Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3. J Acquir Immune Defic Syndr. 2007;46:24-31.
14. Arasteh K, Yeni P, Pozniak A, et al. Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2. and 3 trials at week 96. Antivir Ther. 2009;14:859-64.
15. Currier J, Averitt BD, Hagins D, et al. Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial. Ann Intern Med. 2010;153:349-57.
16. Yazdanpanah Y, Fagard C, Descamps D, et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis. 2009;49:1441-9.
17. Imaz A, Falco V, Ribera E. Antiretroviral salvage therapy for multiclass drug-resistant HIV-1-infected patients: from clinical trials to daily clinical practice. AIDS Rev. 2011;13:180-93.
18. Imaz A, del Saz S, Ribas M, et al. Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection. J Acquir Immune Defic Syndr. 2009;52:382-6.
19. De Meyer S, Lathouwers E, Dierynck I, et al. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients. AIDS. 2009;23:1829-40.
20. De Meyer S, Hill A, Picchio G, DeMasi R, de Paepe E, de Bethune MP. Influence of baseline protease inhibitor resistance on the efficacy of darunavir/ritonavir or lopinavir/ritonavir in the TITAN trial. J Acquir Immune Defic Syndr. 2008;49:563-4.
21. Madruga J, Berger D, McMurchie M, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet. 2007;370:49-58.
22. Banhegyi D, Katlama C, da Cunha C, et al. Week 96 efficacy, virology and safety of darunavir/r versus lopinavir/r in treatment-experienced patients in TITAN. Curr HIV Res. 2012. [E-pub ahead of print].
23. Ortiz R, Dejesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS. 2008;22:1389-97.
24. Mills A, Nelson M, Jayaweera D, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS. 2009;23:1679-88.
25. Orkin C, Dejesus E, Khanlou H, et al. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naive patients in the ARTEMIS trial. HIV Med. 2013;14:49-59.
26. Lathouwers E, De Meyer S, Dierynck I, et al. Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis. Antivir Ther. 2011;16:99-108.
27. Llibre J. First-line boosted protease inhibitor-based regimens in treatment-naive HIV-1-infected patients-making a good thing better. AIDS Rev. 2009;11:215-22.
28. Boffito M, Miralles D, Hill A. Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naive and -experienced patients. HIV Clin Trials. 2008;9:418-27.
29. European AIDS Clinical Society (EACS) Guidelines, version 6.1. November 2012. Available at: http://europeanaidsclinicalsociety.org/. Accessed January 30, 2013.
30. Thompson M, Aberg J, Hoy J, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 2012;308:387-402.
31. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 1-239. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed January 30, 2013.
32. Panel of Experts of GESIDA & Spanish Secretariat for the National Plan on AIDS. Executive summary. Consensus document of GESIDA and SPNS (Spanish Secretariat for the National Plan on AIDS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012). Enferm Infecc Microbiol Clin. 2012;30:315-24.
33. De Meyer S, Spinosa-Guzman S, Vangeneugden T, de Bethune M, Miralles G. Efficacy of once-daily darunavir/ritonavir 800/100 mg in HIV-infected, treatment-experienced patients with no baseline resistance-associated mutations to darunavir. J Acquir Immune Defic Syndr. 2008;49:179-82.
34. Cahn P, Fourie J, Grinsztejn B, et al. Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients. AIDS. 2011;25:929-39.
35. Pulido F, Arribas J, Delgado R, et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. AIDS. 2008;22):F1-9.
36. Mathis S, Khanlari B, Pulido F, et al. Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis. PLoS One. 2011;6:e22003.
37. Gazzard B, Hill A, Anceau A. Cost-efficacy analysis of the MONET trial using UK antiretroviral drug prices. Appl Health Econ Health Policy. 2011;9:217-23.
38. Pasquau J, Gostkorzewicz J, Ledesma F, Anceau A, Hill A, Moecklinghoff C. Budget impact analysis of switching to darunavir/ritonavir monotherapy for HIV-infected people in Spain. Appl Health Econ Health Policy. 2012;10:139-41.
39. Arribas J, Horban A, Gerstoft J, et al. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS. 2010;24:223-30.
40. Clumeck N, Rieger A, Banhegyi D, et al. 96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA < 50 copies/mL at baseline. J Antimicrob Chemother. 2011;66:1878-85.
41. Arribas J, Clumeck N, Nelson M, Hill A, van Delft Y, Moecklinghoff C. The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV-1 RNA copies/mL at baseline. HIV Med. 2012;13:398-405.
42. Pulido F, Arribas J, Hill A, van Delft Y, Moecklinghoff C. Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapy. Antivir Ther. 2011;16:59-65.
43. Pulido F, Arribas J, Hill A, Moecklinghoff C. No evidence for evolution of protease inhibitor resistance from standard genotyping, after three years of treatment with darunavir/ritonavir, with or without nucleoside analogues. AIDS Res Hum Retroviruses. 2012;28:1167-9.
44. Lambert-Niclot S, Flandre P, Malet I, et al. Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 protease. J Antimicrob Chemother. 2008;62:905-8.
45. Arribas J, Hill A, Xi N, van Delft Y, Moecklinghoff C. Interleukin-6 and C-reactive protein levels after 3 years of treatment with darunavir/ritonavir monotherapy or darunavir/ritonavir + two nucleoside reverse transcriptase inhibitors in the MONET trial. J Antimicrob Chemother. 2012;67:1804-6.
46. Arribas J, Pulido F, Hill A, van Delft Y, Moecklinghoff C. Predictors of long-term HIV RNA suppression on darunavir/ritonavir monotherapy in the MONET trial. J Int AIDS Soc. 2012;15:18354.
47. Katlama C, Valantin M, Algarte-Genin M, et al. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS. 2010;24:2365-74.
48. Lambert-Niclot S, Flandre P, Valantin M, et al. Factors associated with virological failure in HIV-1-infected patients receiving darunavir/ritonavir monotherapy. J Infect Dis. 2011;204:1211-16.
49. Lambert-Niclot S, Flandre P, Valantin M, et al. Resistant minority species are rarely observed in patients on darunavir/ritonavir monotherapy. J Antimicrob Chemother. 2012;67:1470-4.
50. Valantin M, Lambert-Niclot S, Flandre P, et al. Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study. J Antimicrob Chemother. 2012;67:691-5.
51. Lambert-Niclot S, Flandre P, Valantin M, et al. Similar evolution of cellular HIV-1 DNA level in darunavir/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeks. PLoS One. 2012;7:e41390.
52. Fox J, Peters B, Prakash M, Arribas J, Hill A, Moecklinghoff C. Improvement in vitamin D deficiency following antiretroviral regime change: Results from the MONET trial. AIDS Res Hum Retroviruses. 2011;27:29-34.
53. Arribas J, Bernardino J, Hill A, Sawyer W, van Delft Y, Moecklinghoff C. Effects of switching to PI monotherapy on measures of lipoatrophy: meta-analysis of six randomized HIV clinical trials. J Int AIDS Soc. 2012; 15:18281.
54. Valantin M, Kolta S, Flandre P, et al. Body fat distribution in HIV-infected patients treated for 96 weeks with darunavir/ritonavir monotherapy versus darunavir/ritonavir plus nucleoside reverse transcriptase inhibitors: the MONOI-ANRS136 substudy. HIV Med. 2012;13:505-15.
55. Bernardino J, Pulido F, Martinez E, et al. Lopinavir-ritonavir plus Abacavir and Lamivudine versus Lopinavir-ritonavir Monotherapy for Recovery of Lipoatrophy in HIV-infected Patients with Sustained Virological Suppression while Receiving Zidovudine/Lamivudine/Abacavir. 19th CROI, Seattle, 2012. [Abstract 846].
56. Perez-Valero I, Bayon C, Cambron I, Gonzalez A, Arribas J. Protease inhibitor monotherapy and the CNS: peace of mind? J Antimicrob Chemother. 2011;66:1954-62.
57. Perez-Valero I, Gonzalez-Baeza A, Estebanez M, et al. Prolonged treatment with boosted protease inhibitor monotherapy is not associated with a higher rate of neurocognitive impairment than triple drug ART. J Int AIDS Soc. 2012;15:18179.
58. Pasquet A, Ajana F, Melliez H, Giurca C, Poissy J, Yazdanpanah Y. Central nervous system HIV replication and HIV-related pachymeningitis in a patient on protease inhibitor monotherapy despite an undetectable plasma viral load. AIDS. 2012;26:1726-8.
59. Bierhoff M, Boucher C, Fibriani A, Ten Kate R. Ongoing HIV replication in cerebrospinal fluid under successful monotherapy. Antivir Ther. 2013. [E-pub ahead of print].
60. Gutmann C, Cusini A, Gunthard H, et al. Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. AIDS. 2010;24:2347-54.
61. Paton N, Meynard J, Pulido F, Arenas-Pinto A, Girard P, Arribas J. Inappropriate claim of 'failure of ritonavir-boosted lopinavir monotherapy in HIV' in the Monotherapy Switzerland/Thailand (MOST) trial. AIDS. 2011;25:393-4.